Evidence map›Paper›PMID 26169912›Full record

ArticleScientific reports2015

Ortho-methylated 3-hydroxypyridines hinder hen egg-white lysozyme fibrillogenesis.

Laura Mariño, Kris Pauwels, Rodrigo Casasnovas, Pilar Sanchis, Bartolomé Vilanova, Francisco Muñoz, Josefa Donoso, Miquel Adrover

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 28 citations in OpenAlex.

  1. Versatile Bifunctional PYTA Derivatives forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Laura MariñoInstitut Universitari d'Investigació en Ciències de la Salut (IUNICS). Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
Kris Pauwels1] Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussel, Belgium [2] VIB Structural Biology Research Centre, Vlaams Instituut voor Biotechnologie, Pleinlaan 2, 1050 Brussel, Belgium.
Rodrigo CasasnovasInstitut Universitari d'Investigació en Ciències de la Salut (IUNICS). Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
Pilar SanchisInstitut Universitari d'Investigació en Ciències de la Salut (IUNICS). Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
Bartolomé VilanovaInstitut Universitari d'Investigació en Ciències de la Salut (IUNICS). Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
Francisco MuñozInstitut Universitari d'Investigació en Ciències de la Salut (IUNICS). Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
Josefa DonosoInstitut Universitari d'Investigació en Ciències de la Salut (IUNICS). Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
Miquel AdroverInstitut Universitari d'Investigació en Ciències de la Salut (IUNICS). Departament de Química, Universitat de les Illes Balears, Ctra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain.
Universitat de les Illes Balears · ESResearch Institute of Health Sciences · ESVrije Universiteit Brussel · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein aggregation with the concomitant formation of amyloid fibrils is related to several neurodegenerative diseases, but also to non-neuropathic amyloidogenic diseases and non-neurophatic systemic amyloidosis. Lysozyme is the protein involved in the latter, and it is widely used as a model system to study the mechanisms underlying fibril formation and its inhibition. Several phenolic compounds have been reported as inhibitors of fibril formation. However, the anti-aggregating capacity of other heteroaromatic compounds has not been studied in any depth. We have screened the capacity of eleven different hydroxypyridines to affect the acid-induced fibrillization of hen lysozyme. Although most of the tested hydroxypyridines alter the fibrillation kinetics of HEWL, only 3-hydroxy-2-methylpyridine, 3-hydroxy-6-methylpyridine and 3-hydroxy-2,6-dimethylpyridine completely abolish fibril formation. Different biophysical techniques and several theoretical approaches are combined to elucidate their mechanism of action. O-methylated 3-hydroxypyridines bind non-cooperatively to two distinct but amyloidogenic regions of monomeric lysozyme. This stabilises the protein structure, as evidenced by enhanced thermal stability, and results in the inhibition of the conformational transition that precedes fibril assembly. Our results point to o-methylated 3-hydroxypyridines as a promising molecular scaffold for the future development of novel fibrillization inhibitors.

Indexed as

AmyloidAnimalsBinding SitesHydrogen-Ion ConcentrationKineticsMicroscopy, Atomic ForceModels, MolecularMolecular Docking SimulationMuramidaseProtein AggregatesProtein Aggregation, PathologicalProtein BindingProtein ConformationProtein StabilityProteolysisPyridines3-hydroxypyridineAmyloidhen egg lysozymeMuramidaseProtein AggregatesPyridines

Identifiers

PMID26169912
PMCPMC4500996
OpenAlexW2254659482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.